文章摘要
贾 冰,孙祖凤,张晓乐,张克勤.伊班膦酸钠与阿仑膦酸钠对绝经后骨质疏松疗效的比较[J].南京医科大学学报,2009,29(5):707~710
伊班膦酸钠与阿仑膦酸钠对绝经后骨质疏松疗效的比较
The comparison of the clinical effects between ibandronate and alendronate in treatment of postmenopausal osteoporosis
投稿时间:2009-01-07  
DOI:10.7655
中文关键词: 骨质疏松  伊班膦酸钠  阿仑膦酸钠  骨密度  血清I型胶原交联C端肽
英文关键词: osteoporosis  ibandronate  alendronate  bone mineral density  CTX-1
基金项目:
作者单位
贾 冰 南京医科大学第一附属医院内分泌科,江苏 南京 210029 
孙祖凤  
张晓乐  
张克勤  
摘要点击次数: 1734
全文下载次数: 221
中文摘要:
      目的:评价伊班膦酸钠与阿仑膦酸钠对绝经后骨质疏松的疗效?方法:绝经后骨质疏松妇女32例,随机分为2组,所有患者每天在接受元素钙500 mg和维生素D 200 IU治疗的同时,分别接受伊班膦酸钠和阿仑膦酸钠治疗,其中伊班膦酸钠150 mg每月1次;阿仑膦酸钠70 mg每周1次?2种药物治疗时间均为1年?通过双能X线吸收仪(DEXA)及血清I型胶原交联C端肽(CTX-1)观察治疗中及治疗后的骨量及骨转换的变化?结果:2组患者经过1年治疗,与用药前比较,腰椎(L2-4)骨量显著上升(P < 0.05),髋部骨量增加但没有统计学意义(P > 0.05):其中伊班瞵酸钠治疗组腰椎L2-4?股骨颈?股骨大转子和全髋骨密度分别上升15.34%?4.15%?5.05%和2.49%;阿仑瞵酸钠治疗组分别上升14.50%?4.42%?1.18%和2.64%;破骨指标血清CTX-1在2组均明显下降(P < 0.05)?2组之间各时点的各部位骨密度值?血清CTX-1值均无统计学差异(P > 0.05)?结论:伊班膦酸钠服用方便,且对于绝经后骨质疏松的治疗效果与阿仑膦酸钠无明显差异?
英文摘要:
      Objective:To evaluate the clinical efficacy of ibandronate and alendronate in postmenopausal osteoporotic women. Methods:A total of 32 postmenopausal women with osteoporosis were randomly classified into two groups,16 in each:group A,oral ibandronate 150 mg per month;and group B,oral alendronate 70 mg per week. All patients received calcium 500 mg and Vitamin D 200 IU daily for one year. All patients were examined by DEXA(lumbar,hip)before and after treatment. At the same time the biochemical marker of bone resorption serum C-terminal telopeptide-I(CTX-1)was determined. Results:The BMD of lumbar spine(L2-4)significantly increased compared with that of pretreatment in both groups(P < 0.05),the BMD of hip locations also increased but without significance. The increases of BMD in ibandronate group were 15.34%,4.15%,5.05%,2.49% at L2-4,femoral neck,trochanter and the total of hip respectively,those in alendronate group were 14.50%,4.42%,1.18%,2.64% respectively; serum CTX-1 levels decreased dramatically in both groups(P < 0.05). The BMD change rates in all locations and the CTX-1 decreases at all time points between the two groups were not significant. Conclusion:Ibandronate is more convenient for long-term use than alendronate,which is as effective as alendronate for increasing bone mineral density and for inhibiting osteoclastic activity in treatment of postmenopausal osteoporosis.
查看全文   查看/发表评论  下载PDF阅读器
关闭